Karo Pharma takes aim at Europe

In a short period of time Karo Pharma has, through expanded strategic acquisitions and organic growth, become established as one of the leading specialty pharma companies in the Nordics. Our ambition is to offer products that improve people’s health and quality of life. We have a commercial focus and specialize on the sales and marketing of prescription drugs (Rx) and over the counter (OTC) products for consumers. Our products are available in over 30 countries.

At Karo Pharma we strive to be cost-conscious and opportunistic. The company is growing organically with established brands that have stable cash flows, as well as through acquisitions and investments in innovative projects with low development risk and short time to market. It is a strategy that has given us solid profitability the past few years and positions us as an attractive partner now that we aim to strengthen our presence in Europe and the rest of the world.

Press releases

11 February, 2019

Karo Intressenter’s proposals ahead of the Extraordinary General Meeting in Karo Pharma on 14 February 2019

EQT VIII[1] through Karo Intressenter AB (”Karo Intressenter”) proposes, ahead of the Extraordinary General Meeting in Karo Pharma Aktiebolag (”Karo…
2 January, 2019

STATEMENT BY THE BOARD OF DIRECTORS OF KARO PHARMA AKTIEBOLAG IN RELATION TO THE INCREASED PUBLIC OFFER FROM EQT VIII, THROUGH KARO INTRESSENTER AB

The Board of Directors of Karo Pharma Aktiebolag has concluded to unanimously recommend that the shareholders of Karo Pharma Aktiebolag…
2 December, 2018

Anders Lönner, chairman of the Board Karo Pharma AB, has suddenly passed away

“It is with great regret and sadness we announce this very tragic and unexpected information”, says the Board of Directors,…

 See all press releases

Reports

14 February, 2019

YEAR-END REPORT 2018

FULL YEAR AND THE FOURTH QUARTER · Net sales amounted to MSEK 1,615.1 (657.6), of which the fourth quarter amounted…
31 October, 2018

INTERIM REPORT JANUARY– SEPTEMBER 2018

THE PERIOD AND THE THIRD QUARTER o EQT VIII has announced a public offer for all shares in Karo Pharma…
19 July, 2018

KARO PHARMA TRIPLES SALES AND PROFIT IN THE SECOND QUARTER

INTERIM REPORT JANUARY – JUNE 2018   THE PERIOD AND THE SECOND QUARTER · Net sales amounted to MSEK 756.5…

 See all reports

About Karo Pharma

Karo Pharma is a profitable and rapidly growing specialty pharma company that contributes to better health and improved quality of life.
Read more

Partnership

We have an opportunistic attitude to partnerships and acquisitions of companies and brands that suit our product portfolio, organization and business strategy.
Read more

Investors

We create stockholder value through regular acquisitions and investments in established products with stable earning potential.
Read more

Products

Locobase

Locobase is a well-established skincare brand, recommended by health care professionals and pharmacy staff. Locobase is an international brand being sold in around 40 countries with a strong position mainly on the Nordic market. Locobase is clinically proven to be gentle to sensitive skin and highly suitable for eczema-prone skin. Locobase is available as Repair,...

Viruseptin

Viruseptin is a dual-acting cold spray that can be used for prevention and treatment of nasal and pharyngeal infections. Viruseptin effectively prevents viruses from spreading and can, if the cold has already broken out, shorten the disease period and reduce the risk of a recurring infection. Viruseptin is the first cold spray that has had...

Paracet

Paracet is Norway’s #1 OTC product (Farmastat/Nielsen, 2017) against headache and pain and is used for short term treatment of mild to moderate pains such as headache, toothache, menstrual pain, muscle- and joint pain. Paracet also decreases fever during a cold or a flu. Paracet is available in different drug forms and strengths, depending on...

View more products